[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349566-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349566-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","domvanalimab-plus-zimberelimab-in-unresectable-and-immunotherapy-refractory-biliary-tract-cancers-a-phase-2-trial","Domvanalimab plus zimberelimab in unresectable and immunotherapy refractory biliary tract cancers: a phase 2 trial","","Phase 2 trial results evaluate domvanalimab (Fc-silent anti-TIGIT) combined with zimberelimab (anti-PD-1) in biliary tract cancers refractory to prior PD-1/L1 therapy (NCT05724563). In 29 evaluable patients, confirmed objective response rate was 10.3% (95% CI 2.2–27.4%), with disease control rate 44.8%. Six-month progression-free survival was 17.2%, and median duration of response was 13.6 months. Treatment-related adverse events occurred in 36.4%, mainly low-grade pruritus and rash. Emergent circulating tumor DNA alterations suggest mechanisms of anti-TIGIT resistance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/domvanalimab-plus-zimberelimab-in-unresectable-and-immunotherapy-refractory-biliary-tract-cancers-a-phase-2-trial/349566/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/domvanalimab-plus-zimberelimab-in-unresectable-and-immunotherapy-refractory-biliary-tract-cancers-a-phase-2-trial/349566.png","ImageObject",300,407,{"name":42,"@type":43},"mieayamfan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What therapy combination was tested in the phase 2 trial?","Question",{"text":63,"@type":64},"The trial tested domvanalimab, an Fc-silent anti-TIGIT antibody, combined with zimberelimab, an anti-PD-1 antibody, in patients with biliary tract cancers refractory to prior PD-1/L1 therapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What were the key efficacy results for the biliary tract cancer cohort?",{"text":68,"@type":64},"Among 29 evaluable patients, the confirmed objective response rate was 10.3% (95% CI 2.2–27.4%) and the disease control rate was 44.8%. The 6-month PFS rate was 17.2%, and the median duration of response was 13.6 months.",{"name":70,"@type":61,"acceptedAnswer":71},"How did safety outcomes look, and what adverse events were most common?",{"text":72,"@type":64},"Treatment-related adverse events occurred in 36.4% of patients and were primarily limited to low-grade pruritus and rash.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349566,1790194008,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090893677,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Article [https://doi.org/10.1038/s41467-026-75554-z](https://doi.org/10.1038/s41467-026-75554-z)  \nDomvanalimab plus zimberelimab in unresectable and immunotherapy refractory biliary tract cancers: a phase 2 trial  \nReceived: 16 December 2025  \n\n| Accepted: 6 July 2026 |\n| --- |\n| |\n| Check for updates |\n\nDavid Hsiehchen 1,2 , John H. Lohrey1,2, Radhika Kainthla1,2,  \nSyed Mohammad Ali Kazmi1,2, Nilesh Verma1,2, Carrie Manwaring2, Chul Ahn2,3 & Hao Zhu 1,2,4  \nT cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor that promotes immune evasion, and dual blockade of TIGIT and PD-1 may restore antitumor immunity. Here we report the primary analysis of the biliary tract cancer cohort from a phase 2 trial (ClinicalTrials.gov registration: NCT05724563) evaluating the Fc-silent anti-TIGIT antibody domvanalimab plus the anti-PD-1 antibody zimberelimab in patients with biliary tract cancers (BTCs) refractory to prior PD-1/L1 therapy. The primary endpoint was conﬁrmed objective response rate (ORR); secondary endpoints included disease control rate(DCR), safety,6-month progression-free survival(PFS), duration of response (DoR), and overall survival. Among 29 evaluable patients, the conﬁrmed ORR was 10.3%(95% CI, 2.2–27.4%), with a DCR of 44.8%. The 6-month PFS rate was 17.2%(95% CI, 6.0–35.8%), and the median DoR was 13.6 months. Treatment-related adverse events occurred in 36.4% of patients and were primarily limited to low grade pruritus and rash. Emergent circulating tumor DNA alterations in RAS signaling, receptor tyrosine kinases, and DNA damage response were identiﬁed as putative mechanisms of anti-TIGIT resistance. Although the prespeciﬁed ORR threshold was not met, the durability of responses, favorable safety proﬁle, and translational ﬁndings support further evaluation of anti-TIGIT–based combination strategies in BTCs.  \nThe incidence ofbiliary tract cancers (BTCs) continues to rise globally, which has been accompanied by an increase in disease-associated mortality1,2. The poor prognosis of BTCs is driven by their high rate of recurrence, even after curative-intent treatment, and the limited efﬁcacy of currently available systemic therapies for advanced diseases3,4. Recent clinical trials have demonstrated the survival beneﬁt of adding anti-PD-1/L1 antibodies with conventional cytotoxic chemotherapy in the treatment of advanced BTCs5,6. However, the improvement in survival and tumor response rates observed with anti-PD-1/L1  \nantibodies is modest, and most patients ultimately experience disease progression5,6.  \nT-cell immunoreceptor with Ig and ITIM domains (TIGIT) is expressed on activated T cells, regulatory T cells, and natural killer cells, where it competes with CD226 for binding to poliovirus receptor (PVR) ligands, thereby promoting an immunosuppressive tumor microenvironment7–10. Through reinforcement of T-cell exhaustion programs, stabilization of regulatory T-cell activity, and suppression of natural killer cell cytotoxicity, TIGIT signaling is hypothesized to  \n1Divison of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA. 2Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. 3Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX, USA. 4Children’s Research Institute, Departments of Pediatrics, Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA. e-mail: [David.hsieh@utsouthwestern.edu](David.hsieh@utsouthwestern.edu)  \nFig. 1 | CONSORT ﬂow diagram. The ﬂow diagram indicates the disposition of patients, including cohorts evaluable for safety and efﬁcacy.  \ncontribute to immune evasion7–9. In primary liver cancer models, TIGITis frequently associated with T cell and natural killer cell dysfunction, including diminished cytokine release, proliferation, and anti-tu","cbCailB2BSxD0mAv","https://ap.wps.com/l/cbCailB2BSxD0mAv","pdf",802643,11,"English","# Phase 2 trial rationale and endpoints\n## Primary and secondary efficacy outcomes\n## Safety and tolerability\n## Mechanisms of resistance using ctDNA\n## Clinical implications","[{\"question\":\"What therapy combination was tested in the phase 2 trial?\",\"answer\":\"The trial tested domvanalimab, an Fc-silent anti-TIGIT antibody, combined with zimberelimab, an anti-PD-1 antibody, in patients with biliary tract cancers refractory to prior PD-1/L1 therapy.\"},{\"question\":\"What were the key efficacy results for the biliary tract cancer cohort?\",\"answer\":\"Among 29 evaluable patients, the confirmed objective response rate was 10.3% (95% CI 2.2–27.4%) and the disease control rate was 44.8%. The 6-month PFS rate was 17.2%, and the median duration of response was 13.6 months.\"},{\"question\":\"How did safety outcomes look, and what adverse events were most common?\",\"answer\":\"Treatment-related adverse events occurred in 36.4% of patients and were primarily limited to low-grade pruritus and rash.\"}]","Domvanalimab plus zimberelimab in unresectable and immunotherapy refractory biliary tract cancers: a phase 2 trial | PDF",1790084333,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/495ebd3db150c831ab641658e999a5fb.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d865b768ec08902f97d3cce47fe9e42e.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fedb2c320a9746272b84cdbd98612ce3.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f9548bdfe66d661c9cc2bb63b82945f.webp",980,1301]